Physician profile
Kit Duong
NPI 1114984051
$656.19
in general payments reported to CMS, 2019-2025
11 companies · $17.80 in 2025
The $17.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.15 · 2022: $169 · 2023: $231 · 2024: $182 · 2025: $17.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.38 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $106.11 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $89.87 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $82.18 | 2022-2023 | Eliquis |
| Astellas Pharma US INC | $67.07 | 2023-2024 | Cresemba |
| Astrazeneca Pharmaceuticals Lp | $56.30 | 2022-2024 | Lokelma, Andexxa |
| Ucb, INC. | $23.87 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.79 | 2024 | Opsumit |
| Merck Sharp & Dohme LLC | $18.58 | 2023 | Verquvo |
| Pfizer INC. | $17.80 | 2025 | |
| Xeris Pharmaceuticals, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kit Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.